The FDA has approved Teva’s QVAR beclomethasone HFA metered dose inhaler with a dose counter for the treatment of asthma, and the company plans to launch the product later in 2014, Teva said.
Teva Global Respiratory Research and Development Senior VP Tushar Shah commented, “Bringing QVAR with a dose counter to market reaffirms Teva’s commitment to addressing unmet needs by providing high-quality and innovative solutions to patients. Adding to our rich heritage within the respiratory space, we are pleased that all Teva Respiratory brands in the U.S. will soon include a dose counter, which will help patients and caregivers track how many doses of their medication remain.”
Read the Teva press release.
